Tag: biotech

BioTech, Finance

Active Biotech Stocks Vertex Pharmaceuticals & Ligand Pharmaceuticals

In this article, we take a look at two stocks which have been in news recently, Vertex Pharmaceuticals & Ligand Pharmaceuticals. Keep an eye out for Vertex Pharmaceuticals (NASDAQ VRTX) and Ligand Pharmaceuticals (NASDAQ LGND) . Vertex has performed really well in the recent weeks, recording almost a 50% rise in its price levels. Ligand has also had some very positive developments revolving around new … Continue reading Active Biotech Stocks Vertex Pharmaceuticals & Ligand Pharmaceuticals

Richard Atkins
BioTech, Finance

Biotech Stocks to Watch AbbVie and MannKind

Off late, Biotech stocks have seen some volatility. Here we look at two promising stocks: Abbvie (NYSE ABBV) and MannKind (NASDAQ MNKD). The two stocks have their fortunes at the opposite end of the spectrum. We take a look at what the future holds for the two stocks. Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders … Continue reading Biotech Stocks to Watch AbbVie and MannKind

Richard Atkins
PRAN NASDAQ PRAN Prana Biotechnology
BioTech, Finance

Biotech Stocks : Top Stocks Arena Pharmaceuticals (NASDAQ ARNA) & Bristol-Myers Squibb (NYSE BMY)

Here in this article, we take a look at two very promising stock: Arena Pharmaceuticals (NASDAQ ARNA) & Bristol-Myers Squibb (NYSE BMY). Arena Pharmaceuticals stock (NASDAQ ARNA) has been slightly lukewarm as off late. But that may change with a relaunch on the horizon. Bristol-Myers Squibb have a lot of projects on the horizon which should see the stock flourish in the coming future. Shares … Continue reading Biotech Stocks : Top Stocks Arena Pharmaceuticals (NASDAQ ARNA) & Bristol-Myers Squibb (NYSE BMY)

Richard Atkins
Biotech stock market news
BioTech, Finance

Biotech Stocks : Review of Johnson & Johnson and Sarepta Therapeutics

In this article, we take a look at two very up and coming stocks in Johnson & Johnson and Sarepta Therapeutics. Keep an eye out for Johnson & Johnson (NYSE JNJ) and Sarepta Therapeutics (NASDAQ SRPT). While at one hand, analysts are optimistic about Johnson & Johnson’s second quarter earnings, Sarepta Therapeutics would be looking to bounce back after some dismal showing recently. With J&J … Continue reading Biotech Stocks : Review of Johnson & Johnson and Sarepta Therapeutics

Richard Atkins
BioTech, Finance

Shire Rejects a $46.5 Billion AbbVie (NYSE:ABBV) Takeover Offer

Goldman Sachs has been hired by Shire as the London-listed drug maker confronts a takeover offer, as explained in the Financial Times morning briefing. Shire turned down a $46 billion bid from Chicago-based AbbVie last week. According to a report from the New-York Times, people briefed on the matter said AbbVie was likely to come back with a higher offer. Allergan, which is fending off … Continue reading Shire Rejects a $46.5 Billion AbbVie (NYSE:ABBV) Takeover Offer

Harvey Dyer
Biotech stock market news
Analysis, BioTech, business, Finance

BioTech Stock News in Video : Valeant (NYSE:VRX) vs Allergan (NYSE:AGN) Takeover Battle, Medtronic (NYSE:MDT) + Covidien (NYSE:COV) $45 Billion Deal in Video + GMO Experiments

A source familiar with the matter said on Saturday, Medical-device maker Medtronic Inc and rival Covidien, are in advanced talks to combine in a deal valued at $45 billion to $50 billion. The person said, asking not to be named because the matter is not public, the deal, which would allow Medtronic to be domiciled in Ireland where Covidien is based and thus take advantage of lower tax rates, could come as soon as Monday. Minneapolis-based Medtronic, which makes cardiovascular and orthopedic devices, has a market value of about $61 billion.

An executive vice-president of Valeant Pharmaceuticals International Inc will leave the company, even as the Canadian drugmaker fends off criticism about management turnover from its takeover target Allergan Inc . Valeant confirmed late on Friday after inquiries by Reuters, Executive vice-president and company group chairman Ryan Weldon will leave. Like Chief Executive Mike Pearson, Weldon previously worked for management consulting firm McKinsey & Co. Valeant said Weldon’s departure was planned, and takes effect after it completes a $1.4 billion sale of several injectable treatments to Nestle SA.

Before residents in southern Oregon overwhelmingly voted to ban genetically modified crops last month, farmers negotiated for months with a biotech company that grows engineered sugar beets near their fields. Their goal was to set up a system to peacefully coexist, an online mapping database of fields to help growers minimize cross-pollination between engineered and non-engineered crops. But the effort between farmers and Swiss company Syngenta failed, leading to the ban. Last October, Oregon Gov. John Kitzhaber directed the state’s Department of Agriculture to undertake something far more ambitious than that failed mapping effort — map GMO field locations across the entire state and establish buffer zones and exclusion areas for GE crops.

Continue reading “BioTech Stock News in Video : Valeant (NYSE:VRX) vs Allergan (NYSE:AGN) Takeover Battle, Medtronic (NYSE:MDT) + Covidien (NYSE:COV) $45 Billion Deal in Video + GMO Experiments”

Harvey Dyer